Percutaneous Device Closure of Paravalvular Leak
-
Published:2016-09-27
Issue:13
Volume:134
Page:934-944
-
ISSN:0009-7322
-
Container-title:Circulation
-
language:en
-
Short-container-title:Circulation
Author:
Calvert Patrick A.1, Northridge David B.1, Malik Iqbal S.1, Shapiro Leonard1, Ludman Peter1, Qureshi Shakeel A.1, Mullen Michael1, Henderson Robert1, Turner Mark1, Been Martin1, Walsh Kevin P.1, Casserly Ivan1, Morrison Lindsay1, Walker Nicola L.1, Thomson John1, Spence Mark S.1, Mahadevan Vaikom S.1, Hoye Angela1, MacCarthy Philip A.1, Daniels Matthew J.1, Clift Paul1, Davies William R.1, Adamson Philip D.1, Morgan Gareth1, Aggarwal Suneil K.1, Ismail Yasmin1, Ormerod Julian O. M.1, Khan Habib R.1, Chandran Sujay Subash1, de Giovanni Joseph1, Rana Bushra S.1, Ormerod Oliver1, Hildick-Smith David1
Affiliation:
1. From Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom (P.A.C., L.S., W.R.D., B.S.R.); Queen Elizabeth Hospital, University Hospitals Birmingham, United Kingdom (P.A.C., P.L., P.C., J.d.G.); Institute of Translational Medicine, University of Birmingham, United Kingdom (P.A.C., P.C.); Royal Infirmary of Edinburgh, Edinburgh, United Kingdeom (D.B.N.); Imperial College NHS Trust, London, United Kingdom (I.S.M.); Evelina Children’s Hospital, London, United Kingdom (S.A.Q., G.M.); The...
Abstract
Background:
Paravalvular leak (PVL) occurs in 5% to 17% of patients following surgical valve replacement. Percutaneous device closure represents an alternative to repeat surgery.
Methods:
All UK and Ireland centers undertaking percutaneous PVL closure submitted data to the UK PVL Registry. Data were analyzed for association with death and major adverse cardiovascular events (MACE) at follow-up.
Results:
Three hundred eight PVL closure procedures were attempted in 259 patients in 20 centers (2004–2015). Patient age was 67±13 years; 28% were female. The main indications for closure were heart failure (80%) and hemolysis (16%). Devices were successfully implanted in 91% of patients, via radial (7%), femoral arterial (52%), femoral venous (33%), and apical (7%) approaches. Nineteen percent of patients required repeat procedures. The target valve was mitral (44%), aortic (48%), both (2%), pulmonic (0.4%), or transcatheter aortic valve replacement (5%). Preprocedural leak was severe (61%), moderate (34%), or mild (5.7%) and was multiple in 37%. PVL improved postprocedure (
P
<0.001) and was none (33.3%), mild (41.4%), moderate (18.6%), or severe (6.7%) at last follow-up. Mean New York Heart Association class improved from 2.7±0.8 preprocedure to 1.6±0.8 (
P
<0.001) after a median follow-up of 110 (7–452) days. Hospital mortality was 2.9% (elective), 6.8% (in-hospital urgent), and 50% (emergency) (
P
<0.001). MACE during follow-up included death (16%), valve surgery (6%), late device embolization (0.4%), and new hemolysis requiring transfusion (1.6%). Mitral PVL was associated with higher MACE (hazard ratio [HR], 1.83;
P
=0.011). Factors independently associated with death were the degree of persisting leak (HR, 2.87;
P
=0.037), New York Heart Association class (HR, 2.00;
P
=0.015) at follow-up and baseline creatinine (HR, 8.19;
P
=0.001). The only factor independently associated with MACE was the degree of persisting leak at follow-up (HR, 3.01;
P
=0.002).
Conclusion:
Percutaneous closure of PVL is an effective procedure that improves PVL severity and symptoms. Severity of persisting leak at follow-up is independently associated with both MACE and death. Percutaneous closure should be considered as an alternative to repeat surgery.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Physiology (medical),Cardiology and Cardiovascular Medicine
Cited by
114 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|